Title :

Tofacitinib for patients with anti-TNF refractory ulcerative proctitis: a multicenter cohort study from the GETAID.

Author(s) :

Uzzan, Mathieu [Auteur]
Institute for Translational Research in Inflammation - U 1286 [INFINITE]
Nachury, Maria [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Nuzzo, Alexandre [Auteur]
Hôpital Beaujon [AP-HP]
Amiot, Aurelien [Auteur]

Caron, Bénédicte [Auteur]
Nutrition-Génétique et Exposition aux Risques Environnementaux [NGERE]
Benezech, Alban [Auteur]
Centre Hospitalier Henri Duffaut (Avignon)
Buisson, Anthony [Auteur]
CHU Clermont-Ferrand
Bouguen, Guillaume [Auteur]
Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou]
Le Berre, Catherine [Auteur]
Centre Hospitalier Universitaire de Nantes = Nantes University Hospital [CHU Nantes]
Reenaers, Catherine [Auteur]
Centre Hospitalier Universitaire de Liège [CHU-Liège]
Le Cosquer, Guillaume [Auteur]
Centre Hospitalier Universitaire de Toulouse [CHU Toulouse]
Savoye, Guillaume [Auteur]
CHU Rouen
Charkaoui, Maeva [Auteur]
Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand [CHU Dijon]
Vidon, Mathias [Auteur]
Centre Hospitalier Intercommunal de Créteil [CHIC]
Guillo, Lucas [Auteur]
Aix Marseille Université [AMU]
Fumery, Mathurin [Auteur]
Université de Picardie Jules Verne [UPJV]
Peyrin-Biroulet, Laurent [Auteur]
Centre Hospitalier Universitaire de Nancy [CHU Nancy]
Kirchgesner, Julien [Auteur]
CHU Saint-Antoine [AP-HP]
Bouhnik, Yoram [Auteur]
Hôpital Ambroise Paré [AP-HP]

Journal title :

Journal of Crohn's and Colitis

Abbreviated title :

J Crohns Colitis

Publication date :

2023-10-13

ISSN :

1876-4479

English abstract : [en]

Background While ulcerative proctitis (UP) can dramatically impair quality-of-life, treatments efficacy has been poorly investigated in UP as it was historically excluded from phase 2/3 randomized controlled trials in ...
Show more >Background While ulcerative proctitis (UP) can dramatically impair quality-of-life, treatments efficacy has been poorly investigated in UP as it was historically excluded from phase 2/3 randomized controlled trials in ulcerative colitis. Aim To assess the effectiveness and safety of tofacitinib for the treatment of UP. Methods We conducted a retrospective multicenter study in seventeen GETAID centers including consecutive patients with UP treated with tofacitinib. The primary endpoint was steroid-free remission between week 8 and week 14, defined as a partial Mayo score of 2 (and no individual subscore above 1). Secondary outcomes included clinical response and steroid-free remission after induction and at one year. Results All the 35 enrolled patients previously received anti-TNF therapy and 88.6% were exposed to at least two lines of biologics. At baseline, the median partial Mayo score was 7 (IQR[5.5-7]). After induction (W8-W14), 42.9% and 60.0% of patients achieved steroid-free remission and clinical response, respectively. At one year, the steroid-free clinical remission and clinical response rates were 39.4% and 45.5%, respectively, while 51.2% (17/33) were still receiving tofacitinib treatment. Survival without tofacitinib withdrawal was estimated at 50.4% (95%CI[35.5-71.6]) at one year. Only a lower partial Mayo at baseline was independently associated with remission at induction (Odds ratio (OR) = 0.56 for an increase of 1, 95% confidence interval (95%CI) [0.33-0.95], p = 0.03). Five (14.3%) adverse events were reported with one leading to treatment withdrawal (septic shock secondary to cholecystitis). Conclusion Tofacitinib may offer a therapeutic option for patients with refractory UP.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

Université de Lille
Inserm
CHU Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Submission date :

2024-01-30T22:04:27Z
2024-03-11T13:31:48Z